It's really a question of money. Governments all over the world did that. And they're willing to spend more money on vacsines than pills. The other thing to be aware of is that the pills themselves were tested on people who are unvaccinated, high risk and at the super earliest stage of cobid. So we don't know that these results arene going to be repeated in the broader population.
Dr. Ian Lustbader, Clinical Professor of Medicine at NYU Langone, discusses why the shot-or-test rule makes sense. Bloomberg Businessweek Editor Joel Weber and Bloomberg News U.S. Health Care Reporter Cynthia Koons explain why Covid pills may save lives, but they won’t end the pandemic. Bloomberg News Health Editor John Lauerman talks about Johnson & Johnson's plan to split off its consumer division, following in the footsteps of other big drugmakers that have moved to focus on the more-profitable pharmaceutical market. Kathy Kraninger, VP of Regulatory Affairs at Solidus Labs, shares her thoughts on crypto manipulation and regulation. And We Drive to the Close with Bill Smead, CIO at Smead Capital Management.
Hosts: Carol Massar and Tim Stenovec. Producer: Paul Brennan.
See omnystudio.com/listener for privacy information.